logo-loader

Zelira Therapeutics halted with capital raising announcement pending

Published: 21:37 02 Feb 2020 EST

Zelira Therapeutics Ltd. - Zelira Therapeutics halted with capital raising announcement pending
Zelira has announced a collaboration agreement with the Parkinson’s Foundation in the US

Zelira Therapeutics Ltd (ASX:ZLD) (OTCMKTS:ZLDAF) (FRA:G1G) is in a trading halt pending the release of a capital raising announcement.

The halt will remain in place until the start of regular ASX trading on Wednesday, February 5, 2020, or when an announcement is released to the market, whichever occurs first.

Zelira, which had a market cap of approximately $48 million, last traded at 6.5 cents, up from 5.2 cents on December 11.

Parkinson's Foundation collaboration

The company recently announced that it would collaborate with the Parkinson’s Foundation in the US to gather insights from people living with Parkinson’s Disease about their understanding of and use of medical cannabis and hemp-derived therapies.

Zelira and the Parkinson’s Foundation will consult on the development of a survey tool to be sent to people with the diseases to understand why and how they are using medical cannabis and hemp-derived CBD products.

They will review the results as they relate to a possible future clinical trial on the safety and efficacy of medical cannabis use by people with Parkinson’s Disease.

Zelira will also incorporate survey insights to inform future development of clinically validated medical cannabis and hemp-derived CBD medicines for people with the disease, and provide guidance to sufferers regarding various cannabinoid-based and hemp-derived CBD treatment alternatives.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

50 minutes ago